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Abstract. 
 
The mammalian guanosine triphosphate 
(GTP)ase-activating protein RanGAP1 is the first ex-
ample of a protein covalently linked to the ubiquitin-
related protein SUMO-1. Here we used peptide map-
ping, mass spectroscopy analysis, and mutagenesis to 
identify the nature of the link between RanGAP1 and 
SUMO-1. SUMO-1 is linked to RanGAP1 via glycine 
97, indicating that the last 4 amino acids of this 101–
amino acid protein are proteolytically removed before 
its attachment to RanGAP1. Recombinant SUMO-1 
lacking the last four amino acids is efficiently used for 
modification of RanGAP1 in vitro and of multiple un-
known proteins in vivo. In contrast to most ubiquiti-
nated proteins, only a single lysine residue (K526) in 
RanGAP1 can serve as the acceptor site for modifica-
tion by SUMO-1. Modification of RanGAP1 with 
SUMO-1 leads to association of RanGAP1 with the nu-
clear envelope (NE)
 
, 
 
where it was previously shown to 
be required for nuclear protein import. Sufficient infor-
mation for modification and targeting resides in a 25-kD 
domain of RanGAP1. RanGAP1–SUMO-1 remains 
stably associated with the NE during many cycles of in 
vitro import. This indicates that removal of RanGAP1 
from the NE is not a required element of nuclear pro-
tein import and suggests that the reversible modifica-
tion of RanGAP1 may have a regulatory role.
 
G
 
tp
 
 hydrolysis by the Ras-related GTPase Ran is es-
sential for transport of proteins into the nucleus
(Melchior et al., 1993
 
a
 
; Moore and Blobel, 1993;
for reviews on transport see Melchior and Gerace, 1995;
Görlich and Mattaj, 1996; Nigg, 1997). Several different
models involving one or multiple rounds of GTP hydroly-
sis by Ran in various regions of the nuclear pore complex
(NPC)
 
1
 
 have been proposed (e.g., Melchior et al., 1995;
Rexach and Blobel, 1995; Görlich and Mattaj, 1996; Koepp
and Silver, 1996). Like many other GTPases, Ran cannot
hydrolyze GTP by itself at a physiologically significant rate
and requires interaction with a GTPase activating protein
for this to occur (Bourne et al., 1990). Therefore, the local-
ization of the GTPase activating protein determines where
GTP hydrolysis by Ran can take place. The only known
GTPase-activating protein for Ran (Becker et al., 1995;
Bischoff et al., 1995), known as RanGAP1 in higher eu-
karyotes and as Rna1p in yeast, has been directly linked to
the import of proteins into the nucleus in mammalian cells
(Mahajan et al., 1997) and 
 
Saccharomyces cerevisiae
 
 (Cor-
bett et al., 1995). Yeast Rna1p is localized predominantly
in the cytoplasm, as judged by cell fractionation and immu-
nolocalization (Hopper et al., 1990; Melchior et al., 1993
 
b
 
).
However, yeast Rna1p may interact, at least temporarily,
with the NPC, since some enrichment of Rna1p around
the nuclear envelope (NE) has been observed by immu-
nofluorescent staining in 
 
S. cerevisiae
 
 and 
 
S. pombe
 
 (Hop-
per et al., 1990; Melchior et al., 1993
 
b
 
) and particularly in
the temperature-sensitive 
 
S. cerevisiae
 
 strain 
 
rna1-1
 
 (Koepp
et al., 1996). In contrast, mammalian RanGAP1 is local-
ized predominantly at the NE, where it forms a stable
complex with the NPC protein RanBP2/Nup358 (Wu et al.,
1995; Yokoyama et al., 1995; Matunis et al., 1996; Mahajan
et al., 1997). Interestingly, the interaction of RanGAP1
with RanBP2 requires the posttranslational modification
of RanGAP1 with SUMO-1 (Mahajan et al., 1997), a small
ubiquitin-related protein that we and others recently iden-
tified under the names Pic1, GMP1, Sentrin, Ubl1, and
SUMO-1, respectively (Boddy et al., 1996; Matunis et al.,
1996; Okura et al., 1996; Shen et al., 1996
 
a
 
; Mahajan et al.,
1997). The finding that the modification of RanGAP1 is
reversible in cell extracts (Matunis et al., 1996; Mahajan et al.,
1997), raises the possibility that the localization of Ran-
GAP1 at RanBP2 may be a dynamic process involved in
the mechanism or regulation of nuclear protein import.
Ubiquitination is the covalent attachment of ubiquitin
to proteins via an isopeptide bond between the COOH-
terminal carboxyl group of ubiquitin and the 
 
e
 
-amino group
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of lysines in the acceptor protein (reviewed in Hershko and
Ciechanover, 1992; Ciechanover, 1994; Hochstrasser, 1995,
1996; Jennissen, 1995; Jentsch and Schlenker, 1995). This
coupling reaction is ATP dependent and involves a series
of enzymatic reactions in which ubiquitin is first activated
by formation of a thioester bond with an E1 enzyme. The
activated ubiquitin is then sequentially transferred to an
E2 enzyme, to a substrate-recognizing E3 enzyme, and fi-
nally to the acceptor protein. The modification is revers-
ible, because the ubiquitin moiety can be removed from
the acceptor molecule by deubiquitinating enzymes.
Modification of proteins with ubiquitin is best known
for its ability to mark substrates for regulated protein deg-
radation by a complex called the 26S proteasome (re-
viewed by Ciechanover, 1994; Hochstrasser, 1995, 1996;
Jentsch and Schlenker, 1995; Hilt and Wolf, 1996). Com-
mitment of a target protein to the degradation pathway in-
volves assembly of a polyubiquitin chain on the target,
usually via isopeptide bonds between lysine 48 of one
ubiquitin and the COOH-terminal glycine residue of the
neighboring ubiquitin. However, it is becoming increas-
ingly evident that the role of the ubiquitin modification is
not limited to the targeting of proteins to the proteasome.
For example, ubiquitination of a yeast plasma membrane
receptor signals its ligand-stimulated endocytosis (Hicke
and Riezman, 1996), and ubiquitination has been shown to
activate a protein kinase involved in I
 
k
 
B
 
a
 
 processing
(Chen et al., 1996).
Recent findings suggest that ubiquitin is part of a family
of related proteins involved in the covalent modification
of proteins. A number of proteins related to ubiquitin
(identities 
 
.
 
35%) have been isolated over the last several
years (e.g., see Kumar et al., 1993; Watkins et al., 1993;
Biggins et al., 1996), among them the 15-kD interferon-
inducible, ubiquitin cross-reacting protein UCRP/ISG15
(Haas et al., 1987). This protein is conjugated to unknown
proteins and may serve as a 
 
trans
 
-acting binding factor
that directs the association of modified target proteins to
intermediate filaments (Loeb and Haas, 1994). More re-
cently, we and others identified a protein that is only very
distantly related to ubiquitin (18% identical), but is never-
theless used for covalent modification. We found that this
protein, which we named SUMO-1 (for small ubiquitin-
related modifier), is covalently linked to RanGAP1, the
GTPase-activating protein for Ran (Matunis et al., 1996;
Mahajan et al., 1997). Two additional mammalian SUMO-
1–related proteins have been identified in DNA-sequenc-
ing projects (Mannen et al., 1996; Lapenta et al., 1997),
and the 
 
S. cerevisiae
 
 SMT3 protein (52% identical to
SUMO-1) has been identified as a multicopy suppressor of
the centromere protein Mif2 (Meluh and Koshland, 1995).
Antibodies raised against SUMO-1 recognize numerous
proteins in buffalo rat liver cell extracts and isolated rat
liver nuclei in addition to RanGAP1 (Matunis et al., 1996;
Mahajan et al., 1997), suggesting that SUMO-1 is coupled
to additional proteins. Candidate proteins are the PML
protein that is linked to promyeolytic leukemia (Boddy et al.,
1996), the Fas/Apo receptors involved in programmed cell
death (Okura et al., 1996), and Rad51 and Rad52 that play
a role in DNA repair (Shen et al., 1996), because they each
interacted with SUMO-1 when used as bait in two-hybrid
interaction screens. Taken together, these findings suggest
that SUMO-1, and possibly SUMO-1–related proteins,
may posttranslationally modify a number of proteins.
Insofar as RanGAP1 is the first known substrate for
modification by SUMO-1, biochemical and functional
characterization of the RanGAP1–SUMO-1 conjugate is
likely to provide a paradigm for other SUMO-1 substrates.
In this study, we characterized the molecular nature of the
link between RanGAP1 and SUMO-1. We found that ly-
sine 526 in the COOH-terminal tail domain of RanGAP1
is linked to glycine 97 of SUMO-1, indicating that despite
the low homology of SUMO-1 to ubiquitin, the character-
istic biochemistry of the link is conserved. Mutation of ly-
sine 526 to arginine completely abolishes modification, in-
dicating that only a single lysine residue in RanGAP1 is
available for modification with SUMO-1. We have also iden-
tified a domain within RanGAP1 that is sufficient both for
modification by SUMO-1 and for targeting to the NE, and
have demonstrated that modified RanGAP1 remains sta-
bly associated with the NE during the course of many cy-
cles of nuclear protein import.
 
Materials and Methods
 
Immunoprecipitation and Peptide Analysis of
SUMO-1–modified RanGAP1
 
RanGAP1 was immunoprecipitated from solubilized rat liver NEs as de-
scribed (Mahajan et al., 1997). Antigen–antibody complexes were sepa-
rated by SDS-PAGE and electroblotted onto polyvinylidene difluoride
membrane. Unmodified and modified RanGAP1 bands were visualized
with Ponceau-S stain and cut out of the membrane. Tryptic digestion and
subsequent analysis of the individual bands was performed by Dr. J.
Leszyk at the Worcester Foundation for Biomedical Research (Shrews-
bury, MA). Proteins were digested in situ with trypsin in a digest buffer
containing 100 mM ammonium bicarbonate, 10% acetonitrile, and 1% hy-
drogenated Triton X-100 (Fernandez et al., 1994). The digest mixture was
separated on a 1 
 
3
 
 250-mm microbore C8 column (Applied Biosystems,
Inc., Foster City, CA) on a modified HPLC system (1090 M; Hewlett-
Packard Co., Palo Alto, CA). Peptides were eluted using a linear gradient
from 100% solvent A (0.1% trifluoroacetic acid in water) to 55% solvent
B (0.08% trifluoroacetic acid in acetonitrile/water 70:30) in 30 min at a
flow rate of 150 
 
m
 
l/min. The eluent was monitored at 210 nm and fractions
were collected manually. A 0.5-
 
m
 
l aliquot of each peptide fraction was
subjected to matrix-assisted laser desorption time-of-flight mass spec-
trometry (MALDI-TOF) using a Linear Biospectrometry Workstation
(Perseptive Biosystems, Cambridge, MA) and alpha cyano-4-hydroxy cin-
namic acid as the matrix. The instrument was calibrated with an external
standard that consisted of angiotensin (MH
 
1
 
 of 1,297.5 D) and Adreno-
corticotropic hormone fragment (amino acids 18–39; MH
 
1
 
 of 2,466.7 D).
Edman sequence analysis was performed on a 494 Procise protein se-
quencer (Applied Biosystems, Inc.).
 
DNA Cloning and Mutagenesis
 
SUMO-1 COOH-terminal deletion mutants were generated by PCR from
SUMO-1 cDNA (Mahajan et al., 1997) and cloned either into pGEX-2T
(Pharmacia Biotech, Inc., Piscataway, NJ) for recombinant expression and
purification, or into pHHS10B (Furukawa and Hotta, 1993) for cytomega-
lovirus promoter-driven expression of NH
 
2
 
-terminal hemagglutinin (HA)-
tagged proteins in transfected eukaryotic cells. Mouse RanGAP1 (fug1;
DeGregori et al., 1994) cDNA constructs representing the NH
 
2
 
-terminal
conserved domain (amino acids 1-416; RanGAP1 body; see Fig. 4) and the
COOH-terminal tail domain present only in RanGAP proteins from
higher eukaryotes (amino acids 400–589; RanGAP1 tail; see Fig. 4) were
generated by PCR from fug1 cDNA (Mahajan et al., 1997). A single-point
mutation to convert lysine 526 to arginine (K526R) was introduced into
both wild-type (wt) RanGAP1 as well as into the RanGAP1 tail domain
using PCR-based, site-directed mutagenesis (Higuchi, 1990). Mutagenesis
reaction products were cloned into pCRII-TA vector (Invitrogen Corp.,
Carlsbad, CA) and sequenced at the Scripps Research Institute core facil- 
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ity. Wt and K526R RanGAP1, body, tail, and K526R tail were cloned into
pHHS10B for HA-tagged eukaryotic expression. In addition, wt and K526R
RanGAP1 were cloned into the prokaryotic expression vector pET-23b
vector (Novagen, Inc., Madison, WI) to express NH
 
2
 
-terminal T7-tagged
recombinant proteins in bacteria.
 
Expression and Purification of Recombinant Proteins
 
RanGAP1 and Gst-GAP-tail were expressed and purified as described
(Mahajan et al., 1997). Wt and mutant T7-tagged RanGAP1 were ex-
pressed in 
 
E. coli
 
 BL21 (DE3) by induction with 0.5 mM IPTG at 30
 
8
 
C for
3 h. Bacteria were harvested by centrifugation, frozen once at 
 
2
 
80
 
8
 
C, and
resuspended to 1/20 the original culture volume in Buffer 1 (50 mM Tris-
Cl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 1 
 
m
 
g/ml
each of leupeptin, pepstatin A, and aprotinin). After addition of 1 mg/ml
lysozyme and incubation on ice for 1 h, the lysate was centrifuged at
100,000 
 
g
 
 for 30 min. The supernatant was used for in vitro shift assays.
Recombinant wt SUMO-1 and SUMO
 
D
 
C4 were expressed and purified as
glutathione-
 
S
 
-transferase (GST) fusion proteins as described for GST–
SUMO-1 (Mahajan et al., 1997). Pure SUMO-1 and SUMO
 
D
 
C4 were ob-
tained by thrombin digestion of the GST-fusion proteins on glutathione
beads according to the manufacturer’s instructions, followed by collection
of the subsequent low speed supernatant.
 
Cell Culture and Transient Transfection of Cos-7 Cells
 
Cos-7 cells were grown in DMEM medium containing 10% FBS (Hy-
clone, Logan, UT) and antibiotics. Transfection of cells with various plas-
mid constructs was carried out using the Superfect Transfection reagent
(QIAGEN Inc., Chatsworth, CA) according to the manufacturer’s in-
structions. Transfections were performed on cells seeded into 6-well tissue
culture plates 12–15 h before use at a density of 2–3 
 
3
 
 10
 
5
 
 cells per well.
For immunofluorescence, cells were plated onto flame-sterilized cover
slips. Cells were typically transfected with 2 
 
m
 
g of endotoxin-free DNA,
incubated with the DNA suspension for 2–3 h, replenished with fresh me-
dium and analyzed 24–48 hours later.
 
Immunoblotting, Indirect Immunofluorescence 
Analysis, and Flow Cytometry
 
For Western blot analysis, transfected cells were washed once with PBS
and then scraped directly in 250 
 
m
 
l hot 2
 
3
 
 Laemmli buffer. Samples were
boiled for 3 min, separated on SDS–polyacrylamide gels, and transferred
to nitrocellulose membranes. Heterologously expressed HA-tagged pro-
teins were identified on immunoblots by probing with an 
 
a
 
-HA mouse
monoclonal antibody (BabCO, Richmond, CA) diluted 1:2,000 in 5%
milk powder in PBS, 0.2% Tween-20. Detection was by enhanced chemi-
luminescence (Pierce Chemical Co., Rockford, IL). Immunoblots of in
vitro modification reactions were assayed using either 0.5 
 
m
 
g/ml 
 
a
 
-Ran-
GAP1 antibodies to detect recombinant untagged RanGAP1 (Mahajan et
al., 1997) or an 
 
a
 
-T7 tag mouse monoclonal antibody (Novagen, Inc.) used
at 1:10,000 to detect T7-tagged wt and mutant RanGAP1. For indirect im-
munofluorescence using light microscopy, transfected Cos-7 cells were
fixed on coverslips with 3.7% formaldehyde in PBS, 1 mM MgCl
 
2
 
 and pro-
cessed as described by Melchior et al., 1995. Expressed HA-tagged pro-
teins were detected using an 
 
a
 
-HA monoclonal antibody (BabCO) at a
1:1,000 dilution. Digitonin permeabilization before fixation involved incu-
bation of the cells with 0.005% digitonin in transport buffer (110 mM
KOAc, 20 mM Hepes, pH 7.3, 2 mM Mg (OAc)
 
2
 
, 0.5 mM EGTA, 2 mM
DTT, 1 
 
m
 
g/ml each of leupeptin, pepstatin, and aprotinin) for 5 min on ice,
and two subsequent washes. For subsequent incubation under nuclear
protein import conditions the permeabilized cells were supplemented with
2.5 mg/ml HeLa cytosol, an ATP regenerating system, and FITC-BSA
conjugated with peptides containing the SV-40 wt nuclear localization sig-
nal, and incubated in a humid chamber at 30
 
8
 
C or on ice (Adam et al.,
1992). After 30 min the cells were fixed with 3.7% formaldehyde in trans-
port buffer, permeabilized with 0.2% triton, and processed for indirect im-
munofluorescence as described above. For flow cytometric analysis, the
cells were trypsinized to bring them into suspension, permeabilized with
digitonin, and subsequently incubated in the presence of 2.5 mg/ml HeLa
cytosol and ATP for 30 min. After 30 min the cells were fixed with 3.7%
formaldehyde in transport buffer, stained with 
 
a
 
-HA mouse monoclonal
antibody (BabCO) and Cy5-conjugated secondary antibodies (Amersham
Corp., Arlington Heights, IL), and analyzed using a FACSort
 
®
 
 flow cytom-
eter (Becton Dickinson, Mountain View, CA).
 
In Vitro Modification of RanGAP1
 
In vitro modification assays were performed as described (Mahajan et al.,
1997). In brief, HeLa suspension cells were permeabilized with 0.07% dig-
itonin in transport buffer at 4 
 
3 
 
10
 
7
 
 cells/ml. This digitonin extract was
supplemented with 1 mM ATP and the respective recombinant proteins
or bacterial lysates and then allowed to incubate for 10 min at room tem-
perature (RT). To examine the ability of various recombinant SUMO-1
proteins to modify RanGAP1, 1 
 
m
 
g of a given purified SUMO-1 protein
was added to a 20-
 
m
 
l modification reaction along with 1 
 
m
 
g recombinant
RanGAP1. To test for resistance of the SUMO-1–RanGAP1 bond to hy-
drolysis, RanGAP1 was shifted with SUMO
 
D
 
C4 and the pH was either in-
creased to 12 with NaOH or treated with 1% hydrazine at RT for 10 min.
For in vitro modification of T7-tagged wt or mutant RanGAP1, 5 
 
m
 
l of the
bacterial lysate from cells expressing either construct (see above) were
added to 20 
 
m
 
l digitonin-extract in the presence of 1 mM ATP. Reactions
were stopped by addition of 2
 
3
 
 Laemmli buffer, and analyzed by immu-
noblotting.
 
Results
 
Identification of the Biochemical Link between 
RanGAP1 and SUMO-1
 
RanGAP1 is presently the only characterized target for
modification by SUMO-1 (or by any of the other proteins
distantly related to ubiquitin). To better understand the
mechanism and regulation of this modification, we de-
cided to map the residues involved in the attachment of
SUMO-1 to RanGAP1. By analogy to ubiquitin, it seemed
plausible that modification of RanGAP1 by SUMO-1 oc-
curred via formation of an isopeptide bond between a
COOH-terminal amino acid of SUMO-1 and the 
 
e
 
-amino
group of a lysine in RanGAP1 (see introduction). How-
ever, considering the extremely low homology of SUMO-1
to ubiquitin (18% identity), alternative links also seemed
possible, particularly since ubiquitin itself seems capable
of forming alternative nonlysine links (Hodgins et al., 1996).
To identify the link between RanGAP1 and SUMO-1,
we carried out peptide analysis. For this, modified and un-
modified RanGAP1 obtained by immunoprecipitation
from rat liver NEs were digested with trypsin, and the
tryptic fragments were separated via chromatography on a
C8 reversed-phase HPLC column. Fig. 1 
 
A
 
 shows a com-
parison of chromatographic profiles of RanGAP1–SUMO-1
(
 
top line
 
) and unmodified RanGAP1 (
 
bottom line
 
). When
chromatographic peaks unique to the RanGAP1–SUMO-1
conjugate were subjected to micropeptide sequencing, we
found that one peak that migrated with a retention time of
27 min (Fig. 1 
 
A
 
, 
 
arrow
 
) apparently contained two peptides
at an equimolar ratio; one from RanGAP1 and one from
SUMO-1. The sequences determined for these two pep-
tides are displayed above the arrow in Fig. 1 
 
A
 
, together
with additional residues that could not be unambiguously
identified (indicated by an X). Since the SUMO-1 peptide
was derived from the COOH-terminal end of SUMO-1, it
seemed possible that the other peptide might represent
the RanGAP1 region to which it was coupled by an iso-
peptide bond. If that were the case, one might expect to
also see disappearance of a peak corresponding to the un-
conjugated peptide in the unmodified RanGAP1. Al-
though this was not observed in the profiles shown here,
after chromatography on a different column (capillary C18
column) we did indeed identify a peptide with the sequence
LLIHMGLLK in the tryptic digest of unconjugated Ran- 
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GAP1 that was absent from conjugated RanGAP1. How-
ever, under those conditions the peak containing the po-
tentially conjugated peptide was not resolved.
To test whether the coeluting peptides were indeed
linked, we performed mass spectroscopy analysis on the
isolated peak fraction (Fig. 1 
 
B
 
). The mass values are sig-
nificantly larger than those expected for either fragment
alone and are consistent with a linked peptide. Our analy-
sis revealed two sets of mass peaks, one with values of
3,634, 3,650, and 3,665 D; and a second with values of
3,878, 3,890, and 3,906 D. The differences in mass among
the three peaks in each set suggested that the two larger
peaks within a given set (labeled [O] in Fig. 1 
 
B
 
) are me-
thionine-oxidation products of the smaller species that are
commonly obtained in gel-purified proteins. By consider-
ing the mass values, sequence information, and predicted
tryptic products of the two proteins, we determined that
the observed mass values correspond to a conjugate con-
taining a single molecule of a SUMO-1 fragment ending at
glycine 97 linked via a covalent bond to a RanGAP1 tryp-
tic fragment that includes either residues 518–530 (3,634-D
peak) or residues 518–532 (3,877-D peak; Fig. 1 
 
B
 
). Since
SUMO-1 is expressed as a 101–amino acid protein that
contains four additional COOH-terminal amino acids be-
yond glycine 97, this demonstrates that SUMO-1 is pro-
teolytically processed before its attachment to RanGAP1.
Both RanGAP1 fragments include an internal lysine (K526)
that appears to be protected from trypsin digestion, indi-
cating that it may be involved in the formation of an
isopeptide bond with SUMO-1. Theoretically, a link could
also be formed via an ester bond involving serine 527.
However, this possibility was ruled out by the resistance of
RanGAP1–SUMO-1 to treatment with either base (pH 12)
or 1% hydrazine, conditions that rapidly hydrolyze ester
bonds (data not shown).
Taken together, these data strongly suggest that SUMO-1
modifies RanGAP1 via an isopeptide bond between the
carboxyl group of glycine 97 of proteolytically processed
SUMO-1 and the 
 
e
 
-amino group of lysine 526 of Ran-
GAP1, as depicted in Fig. 1 
 
C
 
. 
 
SUMO-1 Terminating at Glycine 97 Is Fully Competent 
to Modify RanGAP1 In Vitro
 
To confirm that the attachment of SUMO-1 to RanGAP1
involves glycine 97 and not valine 101 of SUMO-1, and to
determine whether removal of the last four amino acids of
SUMO-1 either precedes or is mechanistically coupled to
its attachment to RanGAP1, we prepared recombinant wt
SUMO-1 along with a mutant SUMO-1 lacking the COOH-
terminal four residues (SUMO
 
D
 
C4). SUMO
 
D
 
C4 termi-
nates in the glycine–glycine motif corresponding to the
COOH-terminal end observed in the peptide analysis (Fig.
1 
 
C
 
), and represents the putative end product of the pro-
teolytically processed protein. First, we tested the ability
of the SUMO-1 proteins to modify recombinant Ran
GAP1 in vitro by monitoring their ability to shift the 70-kD
RanGAP1 to the 90-kD modified form. Recombinant
RanGAP1 was added to a digitonin lysate of HeLa cells in
the presence of ATP and bacterially expressed SUMO-1
proteins (Fig. 2). After 10 min at RT, the reaction products
were analyzed by immunoblotting with 
 
a
 
-RanGAP1 anti-
bodies. Fig. 2 (lane 
 
2
 
) shows that in the absence of exoge-
nously added SUMO-1, 
 
z
 
30–40% of the recombinant
RanGAP1 was converted to the modified 90-kD species
by the endogenous SUMO-1. Addition of exogenous re-
combinant SUMO-1 had only a negligible effect on the
Figure 1. Identification of a linked peptide between RanGAP1
and SUMO-1. (A) Microbore C8 column profile of tryptic digests
of SUMO-1–modified (top profile) and unmodified (bottom pro-
file) RanGAP1, obtained by immunoprecipitation from solubi-
lized rat liver NEs. Asterisks (*) indicate peaks unique to the
SUMO-1–modified RanGAP1 that contain peptides derived
from SUMO-1. Sequencing of the unique peak fraction eluting at
z27 min (arrow) revealed the presence of two distinct sequences,
one from SUMO-1 (ELGMEEDVIEVYXX...) and the other
from RanGAP1 (LLIHGLLX...). (B) Matrix-assisted laser desorp-
tion time of flight (MALDI-TOF) mass spectrometric analysis of
the 27-min peak reveals the presence of two peptides and their
oxidation products (labeled with [O]) with mass values of 3.634 D
(left peaks) and 3,877 D (right peaks). Based on the peptide se-
quences obtained in A and on the known protein sequences of
RanGAP1 (Bischoff et al., 1995, DeGregori et al., 1994) and
SUMO-1 (Mahajan et al., 1997), the observed mass values are
consistent with two linked peptides involving the amino acid resi-
dues drawn above the peaks. (C) Depiction of the predicted
isopeptide bond between the COOH-terminal glycine 97 of
SUMO-1 and lysine 526 of RanGAP1. 
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amount of RanGAP1 converted (Fig. 2, lane 
 
3
 
). In con-
trast, the addition of SUMO
 
D
 
C4 significantly increased
the amount of modified RanGAP1 with a concomitant de-
crease in the amount of unmodified 70-kD RanGAP1
(Fig. 2, lane 
 
4
 
). The effect of SUMO
 
D
 
C4 was even more
striking when the shift assays were performed using GST
fusions of the two forms of SUMO-1. In this case, the
GST-SUMO-1 converts a small amount of RanGAP1 to a
unique 115 kD species (Fig. 2, lane 
 
5
 
). Under the same re-
action conditions the GST-SUMO
 
D
 
C4 converts signifi-
cantly more of the 70-kD RanGAP1 to the 115-kD form
(Fig. 2, lane 
 
6
 
). These data demonstrate that SUMO
 
D
 
C4
can be used as a substrate for the modifying enzymes in
vitro and indicate that proteolytic processing of SUMO-1
is not mechanistically coupled to the conjugation reaction.
 
Moreover, since SUMO
 
D
 
C4 is conjugated to RanGAP1
much more efficiently than wt SUMO-1, the proteolytic
removal of the last four amino acids of SUMO-1 seems
significantly slower than the modification reaction. It re-
mains to be seen whether this processing activity is higher
in different cell extracts.
 
Analysis of COOH-terminal Deletions of SUMO-1
In Vivo
 
To test whether SUMO-1 lacking the last four amino acids
(SUMO
 
D
 
C4) is also an efficient substrate for modification
of RanGAP1 and possibly other proteins in vivo, we ex-
pressed a series of HA epitope-tagged SUMO-1 constructs
in tissue culture cells. HA-tagged wt SUMO-1 was trans-
fected into Cos-7 cells, and the distribution of exogenously
expressed SUMO-1 proteins was detected 24 h after trans-
fection by indirect immunofluorescence microscopy using
an 
 
a
 
-HA monoclonal antibody (Fig. 3 
 
A
 
, 
 
SUMO wt
 
). HA-
tagged SUMO-1 accumulated in intranuclear foci or speck-
les in addition to a diffuse nucleoplasmic distribution (Fig.
3 
 
A
 
). A distinct nuclear rim localization, consistent with
the localization of SUMO-1–modified RanGAP1 (Ma-
tunis et al., 1996; Mahajan et al., 1997), could be observed
in Cos-7 cells expressing low levels of HA–SUMO-1 (Fig.
3 A, 
 
SUMO wt
 
, 
 
bottom
 
). The distribution of HA–SUMO-1
was identical to the localization of endogenous SUMO-1
in untransfected cells (Boddy et al., 1996; Matunis et al.,
1996; data not shown). 
When HA-SUMODC4 was transfected into Cos-7 cells,
its distribution was indistinguishable from wt HA–SUMO-1
(Fig. 3 A, SUMODC4). A strong nuclear signal was de-
tected in .70% of the cells, with staining found diffusely
in the nucleoplasm, nuclear rim, and nuclear speckles as
observed for HA–SUMO-1. Cos-7 cells were also trans-
fected with an HA-tagged SUMO-1 construct lacking six
amino acids at the COOH terminus (SUMODC6). This
construct lacks the conserved glycine doublet required for
conjugation of ubiquitin to its targets and was not ex-
pected to be conjugated to target proteins. Under condi-
tions in which .70% of the cells were successfully trans-
fected, SUMODC6 expression was consistently barely
Figure 2. SUMO-1 lacking the last four amino acids (SUMODC4) is
a better substrate for modification of RanGAP1 in vitro than wt
SUMO-1. Digitonin lysates of HeLa cells were mixed with
RanGAP1 and ATP, and incubated for 10 min at RT in the ab-
sence (lane 2) or presence of wt SUMO-1 (lane 3), SUMODC4
(lane 4), GST–SUMO-1 (lane 5), or GST-SUMODC4 (lane 6).
Lane 1 contains only HeLa extract. Efficiency of conversion of
the 70-kD recombinant RanGAP1 (RanGAP) to a 90-kD
SUMO-1–modified form (RanGAP•SUMO) or a z115-kD
GST–SUMO-1–modified form (RanGAP•GST-SUMO) was as-
sayed by immunoblotting with a-RanGAP1 antibodies.
Figure 3. SUMO-1 and SUMO-
DC4, but not SUMODC6, mod-
ify multiple substrates in vivo.
(A) Immunofluorescence of
Cos-7 cells transfected with
HA-tagged SUMO-1 constructs
and probed with an a-HA
monoclonal antibody. Intracel-
lular localization of wt SUMO-1
(SUMO wt), SUMO-1 with a
six–amino acid COOH-termi-
nal deletion (SUMODC6), and
SUMO-1 terminating at gly-
cine 97 (SUMODC4) was ana-
lyzed. (B) Western blot analy-
sis of SUMO-1–transfected cells.
Cos-7 cells were transfected
with HA-tagged wt SUMO-1 (lane 1), SUMODC6 (lane 2), or SUMODC4 (lane 3), and the cells were lysed in SDS gel loading buffer 24 h
after transfection. Samples were electrophoresed on 8% (top) and 12.5% (bottom) polyacrylamide gels, transferred to nitrocellulose,
and probed with the a-HA monoclonal antibody.The Journal of Cell Biology, Volume 140, 1998 264
visible by immunofluorescence microscopy (Fig. 3 A,
SUMODC6). What protein was detectable was not en-
riched in nuclear structures, but seemed to be equally dis-
tributed throughout the nucleus and cytoplasm. These
findings support the notion that the intranuclear accumu-
lation of SUMO-1 is due to SUMO-1 conjugates rather
than to free SUMO-1. 
This conclusion was further supported by Western blot
analysis of transfected Cos-7 cells with an a HA antibody
(Fig. 3 B). As seen in lane 1 of Fig. 3 B, HA-tagged
SUMO-1 in this cell extract was strongly represented by a
90-kD band that comigrated with modified RanGAP1
(data not shown), as well as in a number of higher molecu-
lar mass bands. We were also able to detect a band at z17-kD
that presumably represents monomeric HA–SUMO-1.
The banding pattern for HA–SUMODC4 was very similar
to that of the wt SUMO-1, demonstrating that SUMODC4
can also be used efficiently by the modification machinery
in vivo (Fig. 3 B, lane 3). In contrast, HA-SUMODC6 was
expressed only in its monomeric form (Fig. 3 B, lane 2).
Similar results were recently reported by Kamitani et al.
(1997).
Interestingly, the levels of unconjugated HA–SUMO-1
and HA–SUMODC6 in the transfected cell extracts were
about the same (Fig. 3 B, bottom panel, lanes 1 and 2),
even though cells contain at least an order of magnitude
more of HA–SUMO-1 due to its presence in protein con-
jugates. The lack of higher levels of unconjugated HA–
SUMODC6 may reflect an instability of the latter, or alter-
natively could indicate that the levels of unconjugated
SUMO-1 are tightly regulated.
A Single Lysine Residue (K526) in RanGAP1 Is 
Modified by SUMO-1
Our peptide analysis of the modified RanGAP1 pointed to
lysine 526 as a potential acceptor site for SUMO-1 in Ran-
GAP1, since it was the only internal lysine residue in the
linked peptide (Fig. 1 C). Lysine 526 resides in the 25-kD
tail of RanGAP1, a domain that is unique to RanGAP pro-
teins of higher eukaryotes (Fig. 4). To unequivocally prove
the identity of the acceptor site, we mutagenized the Ran
GAP1 cDNA at a single base to convert lysine 526 to argi-
nine, and expressed wt RanGAP1 and mutated K526R
RanGAP1 as T7-tagged proteins in bacteria (RanGAP1
derivatives used in this study are shown in Fig. 4). We then
compared the ability of the recombinant proteins to be
modified by SUMO-1 in the in vitro shift assay. For this
experiment, bacterial lysates from cells expressing the T7-
tagged RanGAP1 proteins (Fig. 5, lanes 1 and 2) were
added to digitonin lysates of HeLa cells in the presence of
ATP (Fig. 5, lanes 4 and 5). After incubation at RT for 10
min, the samples were subjected to Western blot analysis.
Under conditions in which z90% of wt RanGAP1 was
modified by SUMO-1 (Fig. 5, lane 4), RanGAP1 K526R
remained completely unmodified (Fig. 5, lane 5), indicat-
ing not only that lysine 526 is the site of modification by
SUMO-1, but that it also is the only site in RanGAP1 ca-
pable of being modified in this in vitro assay. Western blot
analysis of the bacterial extract with a T7-antibodies (Fig.
5, lanes 1 and 2) revealed the presence of a small amount
of a slightly faster migrating species (Fig. 5, open arrow-
head) in addition to full-length RanGAP1 protein. This
species is presumably the result of proteolysis at the COOH-
terminal portion of the protein, since the T7 epitope re-
sides at the NH2 terminus of the recombinant protein and
was still recognized by a T7 antibodies. Interestingly, this
faster migrating species was not modified (Fig. 5, lane 4),
suggesting that the extreme COOH terminus of RanGAP1
may contain information essential for the modification.
SUMO-1 Modification of RanGAP1 at K526 Is 
Required for Targeting RanGAP1 to the Nuclear Rim 
In Vivo
To verify that K526 is the only acceptor site for SUMO-1
modification, and to extend upon our previous data indi-
cating a role for SUMO-1 modification in the targeting of
RanGAP1 to the NPC (Mahajan et al., 1997), we trans-
fected Cos-7 cells with HA-tagged wt and K526R Ran-
GAP1 expression plasmids. Analysis of the cells by indi-
rect immunofluorescence microscopy (Fig. 6 A) and by
Western blot analysis (Fig. 6 B) showed a strikingly differ-
ent distribution for the two proteins. The wt RanGAP1
was localized primarily to the nuclear rim and was also
present in a diffuse cytoplasmic distribution (Fig. 6 A, wt
GAP), consistent with the localization of endogenous
RanGAP1 (Matunis et al., 1996; Mahajan et al. 1997). In
contrast, RanGAP1 containing the lysine 526 to arginine
mutation was unable to localize to the nuclear rim and in-
stead accumulated in the cytoplasm (Fig. 6 A, K526R GAP).
Western-blot analysis of the transfected cells showed that
although both wt RanGAP1 and K526R RanGAP1 were
expressed at equivalent levels, only the wt form of Ran-
GAP1 was competent to be modified in vivo to the 90-kD
form (Fig. 6 B). Taken together, these findings demonstrate
that in vivo SUMO-1 modification of K526 in RanGAP1 is
required to target RanGAP1 to the nuclear envelope.
Figure 4. Schematic representation of RanGAP1 constructs. The
schematic representation of RanGAP1 is based on the sequence
of mouse RanGAP1 (DeGregori et al., 1994) that was used for
this study. Full-length RanGAP1 contains three domains: a leu-
cine-rich repeat domain, a highly acidic stretch, and a 25-kD tail
domain. Although all three domains are present in RanGAP1
proteins from mouse (DeGregori et al., 1994), human (Bischoff
et al., 1995), and Xenopus laevis (Saitoh et al., 1997), homologues
from  S. cerevisiae (Rna1p; Traglia et al., 1989) and S. pombe
(rna1p; Melchior et al., 1993b) contain only the first two domains.
In K526R GAP and K526R tail a single lysine residue in position
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The Tail Domain of RanGAP1 Contains
Both the Modification Site as Well as the Nuclear
Rim-targeting Domain
Next, we investigated the nature of the targeting signal
provided by the SUMO-1 moiety. Our previous in vitro
binding studies did not detect any significant binding of
SUMO-1 alone to RanBP2 (Mahajan et al., 1997) suggest-
ing that SUMO-1 is not simply an adaptor molecule that
links RanGAP1 to RanBP2. Thus, SUMO-1 could serve to
uncover a binding site in RanGAP1 that is masked in the
unmodified protein. Alternatively, modification of Ran-
GAP1 by SUMO-1 could create a composite binding site
that involves both proteins. To begin to address this ques-
tion, we engineered fragments of RanGAP1 (Fig. 4) as
HA-tagged proteins and transfected them into Cos-7 cells
(Fig. 7). The RanGAP1 body contained the first 416 NH2-
terminal amino acids of RanGAP1, including both the leu-
cine-rich repeat domain and the acidic stretch that are
present in all RanGAP1 proteins from yeast to mammals
(Fig. 4). Western blot analysis of transfected cells showed
that this NH2-terminal fragment was expressed at high lev-
els and appeared as a single band somewhat larger than
the predicted molecular mass of z43 kD (Fig. 7 B, body).
This band did not react with a–SUMO-1 antibodies (data
not shown), indicating that it is not SUMO-1 modified.
Cos-7 cells expressing this construct are shown in the left
panels of Fig. 7 A (body). This NH2-terminal fragment was
clearly excluded from the nucleus and did not accumulate
at the nuclear rim. Digitonin permeabilization before fixa-
tion of the cells led to the loss of most of the cytoplasmic
staining and again, no accumulation at the NE was ob-
served (see Fig. 7 C, body). The prominent band observed
by Western blot analysis of digitonin-permeabilized cells
(Fig. 7 D, body) is due to a low level of body that remained
in the cytoplasm after permeabilization (visible in longer
exposures of Fig. 7 C; not shown). Taken together these
data indicate that the conserved NH2-terminal part of Ran-
GAP1 does not contain sufficient information for target-
ing to the NE.
In contrast, a fragment of RanGAP1 representing the
COOH-terminal domain (Fig. 4, GAP tail) exhibited a dis-
tinct nuclear rim localization in addition to intranuclear
accumulation (Fig. 7 A, wt Tail). Digitonin permeabiliza-
tion before fixation of the cells led to loss of the intranu-
clear staining, whereas the nuclear rim staining remained
(see Fig. 7 C, wt Tail). Western blot analysis of transfected
cells showed that the tail fragment was expressed at high
levels and that a small fraction of the wt tail domain was
modified by SUMO-1 (Fig. 7 B, lane 2). Modified tail, but
not unmodified tail, was retained in cells after digitonin
permeabilization (Fig. 7 D, lane 2), indicating that only
SUMO-1–modified tail was localized to the nuclear rim.
A tail domain lacking the SUMO-1 modification site
(Fig. 4, K526R Tail) did not localize to the nuclear rim, but
accumulated within the nucleus (Fig. 7 A, K526R Tail).
The accumulation of the tail fragments in the nucleus upon
overexpression is probably not physiologically relevant,
as full-length RanGAP1 is excluded from the nucleus.
Western blot analysis of transfected cells showed that the
mutant tail fragment was expressed at about the same
level as wt tail (Fig. 7 B, lane 3). Digitonin permeabiliza-
tion before fixation led to a near complete loss of the tail
as judged by immunofluorescence microscopy (Fig. 7 C,
K526R Tail) and by Western blot analysis (Fig. 7 D, lane
Figure 5. A single lysine residue (K526) in RanGAP1 is modified
by SUMO-1. Bacterial lysates of cells expressing T7-tagged wt
RanGAP1 (lanes 1 and 4) or mutant RanGAP1 (lanes 2 and 5)
were mixed with a digitonin lysate of HeLa cells in the presence
of ATP. After a 10-min incubation at RT the reaction products
were analyzed by immunoblotting using mouse monoclonal anti-
bodies against the T7 tag. Lanes 1 and 2, bacterial lysates before
shift reaction; lanes 3–5, extracts after shift reaction. Lane 3,
HeLa extract; lanes 4 and 5, HeLa extract and bacterial extract.
The open arrowhead marks a proteolytic fragment of RanGAP1
that apparently is not competent for modification.
Figure 6. SUMO-1 modification of Ran-
GAP1 at K526 is required for targeting
RanGAP1 to the nuclear rim in vivo. HA-
tagged wt RanGAP1 (wt GAP) and mutant
RanGAP1 (K526R GAP) were transfected
into Cos-7 cells and detected after 24 h. (A)
Localization of transfected HA-tagged pro-
teins by indirect immunofluorescence. Cells
were fixed and probed with an a-HA mono-
clonal antibody. (B) Western blot analysis of
transfected cells. Transfected cells were lysed
by scraping into boiling SDS gel loading
buffer, and analyzed by immunoblotting with
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3). From these experiments we concluded that (a) the tail
domain contains sufficient information to be recognized
by the SUMO-1 modification machinery; (b) the NE-tar-
geting information resides in the tail domain of RanGAP1;
and (c) modification with SUMO-1 is required not only for
targeting of full-length RanGAP1 but also for targeting of
the much shorter tail fragment. 
SUMO-1–modified RanGAP1 Remains Stably Bound to 
the NE During In Vitro Nuclear Protein Import
The finding that the modified tail domain remained stably
associated with the NE upon digitonin permeabilization
and washing of the cells (Fig. 7 C, wt Tail and D, lane 2)
suggested that there was no rapid demodification during
the treatment. To test whether this was also true for full-
length RanGAP1 under conditions that allow nuclear pro-
tein import, Cos-7 cells transfected with full-length HA-
tagged RanGAP1 were permeabilized with digitonin and
mixed with HeLa cytosol, ATP, and a fluorescent trans-
port substrate (FITC-BSA-NLS), and incubated in the
presence or absence of recombinant untagged wt Ran-
GAP1 (Fig. 8). After incubation of the mixture at the indi-
cated temperature for 30 min, the cells were fixed and the
amount of HA-tagged RanGAP1 in these cells was ana-
lyzed quantitatively by flow cytometry. As shown in the
top panel of Fig. 8 A, which shows cells that were kept at
0°C, expression of HA-tagged RanGAP1 resulted in a
large number of cells that show higher levels of HA-signal
compared with background in mock-transfected cells (bot-
tom panel). This is consistent with a transfection efficiency
of z50%, which is also suggested by the indirect immuno-
fluorescence staining shown in Fig. 8 B. Both analysis by
flow cytometry and by indirect immunofluorescence showed
a high variation of the HA-signal (note the logarithmic
scale in Fig. 8 A), indicating a high cell to cell variability in
expression levels. Incubation for 30 min at 308C to carry
out nuclear protein import did not alter the HA signal dis-
tribution, even in the presence of an excess of recombinant
untagged RanGAP1. Fig. 8 B shows analysis of a similar
experiment by immunofluorescence. In each field both
transfected and untransfected cells are present, indicating
that no redistribution of RanGAP1 occurs under condi-
tions that clearly allow many cycles of nuclear protein im-
port (see Discussion). Although the overall cell to cell
variation in nuclear import levels was quite high both in
transfected and untransfected cells, strong nuclear accu-
mulation of transport substrate occurred in cells that re-
tained high levels of HA-RanGAP1 at the NE (Fig. 8 B,
middle and bottom). These findings indicate that the NE-
associated RanGAP1–SUMO-1 conjugate is not rapidly
turned over under in vitro import conditions, and allows
the conclusion that modification and demodification of
RanGAP1 is not a required element of nuclear protein im-
port.
Discussion
Identification of the RanGAP1–SUMO-1 Link Reveals 
Similarity to Ubiquitination
We found that despite the low homology of SUMO-1 to
ubiquitin, the general characteristics of SUMO-1 conjuga-
Figure 7. The mammalian-specific tail region of
RanGAP1 is both necessary and sufficient for
SUMO-1 modification and nuclear rim target-
ing. (A) Immunofluorescence of Cos-7 cells
transfected with HA-tagged RanGAP1 con-
structs representing the NH2-terminal 416
amino acids (Body), the COOH-terminal tail re-
gion containing amino acids 400-589 (wt Tail),
and a mutant tail lacking the SUMO-1 modifica-
tion site (K526R Tail). Transfected cells were
fixed and probed with the a-HA monoclonal
antibody. (B) Western blot analysis of trans-
fected cells separated on a 12.5% polyacryla-
mide gel. Cells were transfected as above, lysed
in boiling SDS gel loading buffer and analyzed
by immunoblotting with a-HA monoclonal anti-
body. (C) Immunofluorescence of digitonin per-
meabilized Cos-7 cells transfected with the Ran-
GAP1 constructs. Cells were permeabilized
with 0.05% digitonin for 6 min, washed 33 in
PBS before fixation, and then processed for im-
munofluorescence. (D) Immunoblots of digito-
nin-permeabilized transfected cells. Cells were
permeabilized as described for immunofluores-
cence analysis, lysed in SDS gel loading buffer,
and analyzed by immunoblotting with a-HA
monoclonal antibodies. (B and D) Arrowheads
indicate the positions of unmodified tail (open
arrowhead) and modified tail (closed arrow-
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tion (summarized in Fig. 9) seem to be identical to those of
ubiquitination. Ubiquitin is expressed as a polyubiquitin
moiety or as an NH2-terminal fusion to unrelated proteins
and must be proteolytically processed to release mono-
meric ubiquitin and to reveal the COOH-terminal Gly-
Gly motif that is involved in coupling to targets (e.g., Oz-
kaynak et al., 1984; Monia et al., 1989; Callis et al., 1995).
In comparison, SUMO-1 is expressed as a single 101–amino
acid protein that contains 4 additional COOH-terminal
amino acids beyond the Gly-Gly motif that it shares with
ubiquitin (Mahajan et al., 1997). In principle, any free car-
boxyl group may be used for the formation of an isopep-
tide bond, and a ubiquitin mutant with a COOH-terminal
alanine instead of glycine can be used as a substrate for
ubiquitination (Hodgins et al., 1992). Therefore, it was
conceivable that full-length SUMO-1 was used for modifi-
cation. However, the identification of a branched peptide
between RanGAP1 and SUMO-1 clearly indicates that
the last four amino acids of SUMO-1 are removed to re-
veal the Gly-Gly motif before its attachment to RanGAP1.
After proteolytic processing, the COOH-terminal glycine
97 in SUMO-1 is conjugated to a lysine residue in the ac-
ceptor protein RanGAP1 via an isopeptide bond. The sim-
ilarity of the SUMO-1 modification to ubiquitination sug-
gests that some of the multiple enzymes thought to be
involved in ubiquitination and deubiquitination may use
SUMO-1 or other ubiquitin-related proteins instead. The
recent finding that Ubc9, an E2-like enzyme implicated in
ubiquitin-mediated cyclin degradation (Seufert et al., 1995),
can be found in a complex with SUMO-1–modified Ran-
GAP1 and RanBP2 (Saitoh et al., 1997), and interacts with
SUMO-1 in a two-hybrid interaction screen (Shen et al.,
1996b) may support this possibility.
Proteolytic processing of SUMO-1 is not mechanisti-
cally coupled to the conjugation reaction, as a truncated
version of SUMO-1 lacking the last four amino acids is ef-
ficiently conjugated to RanGAP1 in vitro (this study) and
to other unknown proteins in vivo (Kamitani et al., 1997).
Interestingly, in in vitro shift assays, SUMO-1DC4 is con-
jugated to RanGAP1 much more efficiently than wt
SUMO-1, suggesting that proteolytic processing in the
HeLa cell lysate is significantly slower than the enzymatic
reactions leading to the formation of the isopeptide bond
between SUMO-1 and RanGAP1. It remains to be seen
whether the same enzyme that carries out proteolytic pro-
cessing of full-length SUMO-1 is also able to cleave the
RanGAP1–SUMO-1 conjugate. This dual activity has been
demonstrated for at least one of the large number of deu-
biquitinating enzymes (Hochstrasser, 1996). If this were
the case, it would seem plausible that the rate of such an
enzyme is significantly lower than the rate of the modifying
enzymes that lead to production of modified RanGAP1.
Multiple Proteins Can Be Modified by SUMO-1
The overexpression of HA-tagged SUMO-1 in Cos-7 cells
gives rise to multiple protein bands containing the HA
epitope (this study; Kamitani et al., 1997). Since this is de-
pendent on the presence of the double glycine motif in
SUMO-1, it strongly indicates that SUMO-1 can modify mul-
tiple proteins. We cannot rule out that some of the bands
may represent a single protein modified with SUMO-1
chains of various length. However, it is unclear whether
SUMO-1 is capable of forming such polymeric chains,
since none of the lysines shown to be used for ubiquitin–
ubiquitin links (positions 6, 11, 29, 48, and 63 in ubiquitin;
Arnason and Ellison, 1994; Spence et al., 1995; Baboshina
and Haas, 1996) are conserved in SUMO-1. Moreover, an-
tibodies to RanGAP1 consistently detect only a mono-
modified form, even after incubation of RanGAP1 with
Figure 8. Stable association
of modified RanGAP1 with
the NE during nuclear pro-
tein import. (A) Analysis of
Cos-7 cells transfected with
HA-tagged RanGAP1 by flow
cytometry. Cos7 cells trans-
fected with HA-RanGAP1
(A, top three panels), or
mock-transfected cells (bot-
tom panel) were permeabi-
lized with digitonin and incu-
bated in the presence of
cytosol and ATP at the indi-
cated temperature. To one
sample recombinant Ran-
GAP1 was added (308C 1
RanGAP1). After 30 min, the
cells were fixed and stained
with  a-HA monoclonal anti-
body and Cy5-conjugated secondary antibodies. The cell-associated Cy5 signal was detected by flow cytometry. (B) Analysis of nuclear
import in Cos-7 cells transfected with HA-tagged RanGAP1. Cos7 cells transfected with HA-RanGAP1 were permeabilized with digi-
tonin and incubated in the presence of cytosol, ATP, and FITC-labeled import substrate at the indicated temperature. To one sample
recombinant RanGAP1 was added (308C 1 RanGAP1). After 30 min, the cells were fixed, and processed for indirect immunofluores-
cence using a-HA monoclonal antibody. Arrows indicate corresponding cells in each set and are provided for orientation.The Journal of Cell Biology, Volume 140, 1998 268
cell lysates in the presence of a large excess of SUMO-
1DC4. The finding that antibodies raised to SUMO-1
recognize numerous bands on Western blots (Matunis et al.,
1996; Mahajan et al., 1997), as well as immunolocalization
studies of endogenous or overexpressed HA-tagged SUMO-1
(Boddy et al., 1996; Matunis et al., 1996) also are consis-
tent with the interpretation that other proteins besides
RanGAP1 are modified. The predominantly nuclear local-
ization of SUMO-1 and particularly its concentration in
nuclear speckles and at the NE seems to be dependent on
the conjugation of SUMO-1 to other proteins, since we
find that free HA-tagged SUMO-1DC6 lacking Gly97 is not
enriched in those regions (this study). Moreover, SUMO-1
has been found to interact with a number of proteins in
two-hybrid interaction screens and colocalizes with one of
them, the PML protein, in nuclear bodies (Boddy et al.,
1996).
Considered together, these results strongly support the
notion that SUMO-1 can modify multiple proteins. How-
ever, at least two additional proteins closely related to
SUMO-1 exist in mammalian cells (Mannen et al., 1996;
Lapenta et al., 1997), and some of the results could be due
to antibody cross-reactivity. Overexpression of SUMO-1
may also cause incorporation of SUMO-1 into proteins
where a SUMO-1–related species would normally be used.
A Single Lysine in RanGAP1 Serves as an Acceptor Site 
for SUMO-1
Peptide mapping and mass spectroscopy strongly suggest
that the isopeptide bond between RanGAP1 and SUMO-1
is formed on lysine 526 in the tail domain of RanGAP1.
Mutation of that lysine residue to arginine completely
abolished the modification both in vivo and in vitro, con-
firming lysine 526 as the acceptor site and indicating that
no alternative lysine residue in RanGAP1 can substitute
as the acceptor site, despite the fact that several additional
lysine residues are close by. It remains to be seen whether
the acceptor site is characterized by a specific recognition
site for the modifying enzyme or merely by accessibility of
the lysine residue. The apparent specificity of the acceptor
site is consistent with the finding that SUMO-1 serves to
alter the binding properties of RanGAP1 rather than to
mark it for degradation (see Fig. 9 and below).
Although only a small number of acceptor sites for ubiq-
uitination have been identified, it seems that the ubiquiti-
nation machinery is rather promiscuous with respect to
acceptor site choice (Ciechanover, 1994). Analysis of ubiq-
uitin-mediated degradation of cyclin B (King et al., 1996)
and of the T cell antigen receptor z chain (Hou et al., 1994)
demonstrates that multiple lysine residues can function as
acceptor sites and that each is sufficient to target the pro-
tein for rapid degradation. In addition, ubiquitination of
either one of two adjacent lysines in I k B is sufficient for
degradation (Baldi et al., 1996).
RanGAP1 Tail Is Sufficient Both for Modification by 
SUMO-1 and for Targeting to the NE
RanGAP1 is localized predominantly at the NE, where it
forms a complex with the nuclear pore complex protein
RanBP2. We have shown previously that modified but not
unmodified RanGAP1 binds to RanBP2 in vitro (Mahajan
et al., 1997, see also Fig. 9). Identification of the acceptor site
in RanGAP1 (K526) for SUMO-1 modification allowed us
to extend those studies to in vivo experiments. We found
that SUMO-1–modified wt RanGAP1 and SUMO-1–modi-
fied RanGAP1 tail, but not K526R RanGAP1, K526R tail,
or GAP body are targeted to the NE upon expression in
Cos-7 cells. Since SUMO-1 by itself does not bind to
RanBP2 (Mahajan et al., 1997), these findings indicate that
essential targeting information resides in the tail domain
of RanGAP1. Whether SUMO-1 serves to unmask a bind-
ing site present in the tail, or whether a binary binding site
is formed upon modification that contains elements of
both the GAP tail and SUMO-1 remains to be seen. The
finding that RanGAP1 lacking the tail domain is exclu-
sively cytoplasmic is reminiscent of the cytoplasmic local-
ization of the yeast RanGAP homologues that do not con-
tain a homologue of the tail domain (see Introduction and
Fig. 4). Although it is possible that yeast RanGAP may be
able to fulfill its role in nuclear import while in the cyto-
plasm, we consider it more likely that a different, less sta-
ble targeting mechanism is used. One possibility is that a
separate protein homologous to the tail domain of Ran-
GAP1 serves as an adapter between Rna1p and its puta-
tive binding partner at the NPC. This protein may or may
not be modified with the yeast SUMO-1 homologue SMT3.
Alternatively, since no obvious homologue for RanBP2,
the RanGAP1 binding partner at the NPC in higher eu-
karyotes, has been found in yeast, the targeting mecha-
nisms could be quite distinct.
Figure 9. SUMO-1–mediated targeting of RanGAP1 to the nu-
clear pore complex protein RanBP2. After SUMO-1 is proteoly-
tically processed at the COOH terminus to expose glycine 97, it
serves as the substrate in the ATP-dependent formation of an
isopeptide bond between the free carboxyl group of glycine 97 in
SUMO-1 and the e-amino group of lysine 526 in the tail domain
of RanGAP1. Modified RanGAP1 binds stably to RanBP2 at the
cytoplasmic fibrils of the NPC through an interaction mediated
by the SUMO-1–modified tail domain of RanGAP1. While the
modification reaction is reversible, it remains to be seen whether
RanGAP1 can be demodified after it has associated with RanBP2.Mahajan et al. SUMO-1 Modification of RanGAP1 269
A Role for the Reversible Modification of
RanGAP1 with SUMO-1 in the Regulation of Nuclear 
Protein Import?
In analogy to ubiquitination, it is appealing to speculate
that modification of RanGAP1 with SUMO-1 is revers-
ible. In fact, demodifying activity has been observed in
vitro, both in cell extracts and solubilized NEs (Matunis
et al., 1996; Mahajan et al., 1997). Although it remains to
be seen whether the RanGAP1–SUMO-1 associated with
RanBP2 is susceptible to demodification (Fig. 9), two dis-
tinct roles could be envisioned for such a reversible SUMO-1
modification of RanGAP1. In one scenario, modification
and demodification could be mechanistically linked to the
nuclear import process. If this were the case, the turnover
of modified RanGAP1 at the NE would have to be very
rapid, since in vitro nuclear import rates are z30 mole-
cules per pore complex per minute (Melchior et al., 1993a).
However, our data strongly argue against such a direct re-
quirement of a modification/demodification cycle in nu-
clear protein import, since SUMO-1–modified RanGAP1
remains stably bound to the NE under conditions that al-
low many cycles of nuclear protein import. These data, to-
gether with the finding that soluble RanGAP1 is not re-
quired for in vitro nuclear import and the observation that
antibody inhibition of NPC associated RanGAP1 inhibits
nuclear protein import (Mahajan et al., 1997), strongly
support the possibility that RanGAP1-mediated GTP hy-
drolysis by Ran in nuclear protein import is restricted to
RanBP2.
An intriguing alternative for the function of SUMO-1 is
that the reversible modification of RanGAP1 could serve
to regulate nuclear protein import in response to the cellu-
lar state. Downregulation of nuclear import has been ob-
served, for example, when cells exit the cell cycle due to
contact inhibition or serum starvation (Feldherr and Akin,
1994). Since the localization of RanGAP1 at RanBP2 seems
to be critical for nuclear protein import (Mahajan et al.,
1997), regulated modification and demodification could di-
rectly affect the overall rate of Ran-dependent nuclear
protein import by controlling the proportion of RanBP2
molecules that are complexed with RanGAP1.
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